Study on Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Acute Myeloid Leukemia (AML) That Has Returned or Not Responded to Treatment

Exclusion Criteria

• Have received previous therapy other than Venetoclax combined with a hypomethylating agent, or Venetoclax followed by IDH or FLT3 inhibitors.
• Have had any anti-cancer treatment within 14 days before starting the study treatment. However, hydroxyurea is allowed during the first cycle if needed to control the disease.
• Have significant heart problems, such as severe heart failure, recent heart attack, or uncontrolled high blood pressure.
• Have any uncontrolled infections, whether bacterial, fungal, or viral.
• Have HIV or active hepatitis B or C infections.
• Have ongoing severe side effects from previous treatments that are not easily managed, except for hair loss, nausea, and fatigue.
• Have another active cancer or a history of cancer that could interfere with the study results. Certain non-threatening cancers like non-melanoma skin cancer or localized prostate cancer are exceptions.
• Have uncontrolled lung diseases that could increase the risk of complications during the study.
• Have known or suspected active disease in the central nervous system (CNS).
• Are taking immunosuppressive medications, except for low-dose prednisone (10 mg/day or less).
• Have had an allogenic stem cell transplant before the treatment.
• Have any other uncontrolled illnesses or conditions that could interfere with the study, including severe infections or psychiatric issues.
• Are pregnant or breastfeeding.